Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Durect Corp. (DRRX)
NASDAQ:DRRX
Durect (DRRX) Stock Price & Analysis
1,420 Followers
DRRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.47 - $7.46
Previous Close$0.93
Volume177.94K
Average Volume (3M)139.41K
Market Cap
$28.87M
Enterprise Value$13.04M
Total Cash (Recent Filing)$38.98M
Total Debt (Recent Filing)$23.15M
Price to Earnings (P/E)-0.9
Beta1.32
Next Earnings
Aug 01, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding31,039,381
10 Day Avg. Volume134,799
30 Day Avg. Volume139,407
Standard Deviation0.29
R-Squared0.03
Alpha0.00341
Financial Highlights & Ratios
Price to Book (P/B)3.56
Price to Sales (P/S)8.71
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.42
Enterprise Value/Gross Profit0.74
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$5.00Price Target Upside437.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Durect News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsMortality reductions at 90 days were significant in the U.S. enrolled patients during the AHFIRM study.
Regulatory MilestoneFDA confirmed a single pivotal Phase 3 trial would sufficiently support larsucosterol's U.S. approval for alcohol-associated hepatitis (AH).
Strategic CollaborationCollaboration with Charles River could drive ALZET's growth while DURECT focuses on larsucosterol.
Bears Say
Clinical Trial ResultsLarsucosterol failed to meet the primary and key secondary efficacy endpoints in the Phase 2b AHFIRM study, raising concerns about its effectiveness.
Drug EfficacyEfficacy concerns intensify as the higher dose of larsucosterol showed weaker results than the lower dose in clinical trials.
Regulatory PathwayUncertainty looms over the regulatory future of larsucosterol after missing crucial efficacy endpoints, casting doubt on its approval prospects.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DRRX FAQ
What was Durect Corp.’s price range in the past 12 months?
Durect Corp. lowest stock price was $0.47 and its highest was $7.46 in the past 12 months.
What is Durect Corp.’s market cap?
Currently, no data Available
When is Durect Corp.’s upcoming earnings report date?
Durect Corp.’s upcoming earnings report date is Aug 01, 2024 which is in 75 days.
How were Durect Corp.’s earnings last quarter?
Durect Corp. released its earnings results on May 13, 2024. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.205 by -$0.045.
Is Durect Corp. overvalued?
According to Wall Street analysts Durect Corp.’s price is currently Undervalued.
Does Durect Corp. pay dividends?
Durect Corp. does not currently pay dividends.
What is Durect Corp.’s EPS estimate?
Durect Corp.’s EPS estimate is -$0.16.
How many shares outstanding does Durect Corp. have?
Durect Corp. has 31,039,381 shares outstanding.
What happened to Durect Corp.’s price movement after its last earnings report?
Durect Corp. reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.205. Following the earnings report the stock price went down -14.019%.
Which hedge fund is a major shareholder of Durect Corp.?
Among the largest hedge funds holding Durect Corp.’s share is Moore Capital Management LP. It holds Durect Corp.’s shares valued at N/A.
---
Durect Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (437.63% Upside)
$5.00 (437.63% Upside)
Blogger Sentiment
Bullish
DRRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 75.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.45%
12-Months-Change
Fundamentals
Return on Equity
-196.94%
Trailing 12-Months
Asset Growth
-37.92%
Trailing 12-Months
Company Description
Durect Corp.
DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
---
DRRX Earnings Call
Q1 2024
0:00 / 0:00
---
DRRX Stock 12 Month Forecast
Average Price Target
$5.00
▲(437.63% Upside)
Technical Analysis
Alnylam Pharma
―
Anika Therapeutics
―
Aurinia Pharmaceuticals
―
Avadel Pharmaceuticals
―
Best Analysts Covering DRRX
1 Year
1 Year Success Rate
2/16 ratings generated profit
1 Year Average Return
-43.25%
reiterated a buy rating 5 days ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -43.25% per trade.
---